The buzz at the ISPOR Europe 2023 conference in Copenhagen was all about the proposed EU pharma legislation review. This legislation, proposed at a potentially turbulent time, aims to reshape the healthcare landscape in Europe. But has encountered significant resistance from the pharmaceutical industry. The industry is also grappling with the simultaneous implementation of the joint Health Technology Assessment regulation (HTAR).
The panel at the conference highlighted the difficulty of balancing industry and health policies, particularly concerning affordability and sustainability. They concurred that the proposed legislation did little to rectify the misalignment issues, which are further complicated by geopolitical considerations and a lack of clarity in the legislation review.
Neil Grubert, an independent Global Market Access Consultant, representing the industry perspective, expressed concern about the potential pressure on joint clinical assessment (JCA) timelines due to the expedited timelines proposed in the review. He highlighted the need to consider the global context, particularly as Europe has lost ground to the U.S. in R&D spend and launches.
Yannis Natsis, Director of the European Social Insurance Platform (ESIP), termed the interplay between industry policy and health policy as “complex”. He criticised the legislation for being rushed and for having weak evidence requirements, leading to high prices for certain medicines. He called for more interaction and collaboration between HTA, regulators, payers, and the industry.
Johan Pontén, International Co-ordinator at Sweden’s Dental and Pharmaceutical Benefits Agency, (TLV), expressed concern about the increasing expenditure and drug prices, coupled with lower evidence on effectiveness being presented for assessments. He argued for the compulsory requirement to conduct a comparative study instead of the proposed incentive.
The panel agreed that the lack of clarity in the legislation is causing confusion about potential consequences. While the legislation could lead to significant changes, stakeholders are currently in a grey zone. They are anticipating the switch without the necessary tools or knowledge to take precautionary actions.
🤔 How can deep learning transform diabetes diagnosis?
Discover the innovative DiaNet v2 model, which leverages retinal images to accurately diagnose diabetes with over 92% accuracy! This non-invasive approach has the potential to improve health outcomes, especially in regions where traditional methods are less accessible. Join us in exploring how technology can revolutionise diabetes management.
#SyenzaNews #AIinHealthcare #DigitalHealth #HealthcareInnovation #DiabetesManagement
🌍 How is international collaboration shaping the fight against the mpox outbreak in Africa?
Discover the latest efforts from Africa CDC and the Ministry of Health, Singapore, to address this pressing health challenge. Their partnership includes critical support such as diagnostic kits and a comprehensive response plan, demonstrating the power of global cooperation in public health. Together, we can enhance diagnostics and strengthen case management to protect the communities most affected.
#SyenzaNews #globalhealth #healthcare #innovation
🌍 Are you aware of the alarming rise in diabetes cases, particularly in the Middle East and North Africa?
A recent article from the WHO highlights that global diabetes cases have quadrupled since 1990, with nearly 450 million adults going untreated. There’s an urgent need for policy changes and improved health systems to combat this escalating health crisis. Explore the challenges and actions needed to address this significant public health issue.
#SyenzaNews #DiabetesAwareness #GlobalHealth #PublicHealth #MENA
SPEAK WITH US
CORRESPONDENCE ADDRESS
1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA
WRITE US
JOIN NEWSLETTER
